Format

Send to

Choose Destination
Vaccine. 2018 May 3;36(19):2712-2720. doi: 10.1016/j.vaccine.2018.02.075. Epub 2018 Apr 5.

Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.

Author information

1
Department of Molecular and Medical Virology, Ruhr-University Bochum, Universitätsstraße 150, 44790 Bochum, Germany; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Schloßgarten 4, 91054 Erlangen, Germany.
2
Institute for Virology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
3
Sirion Biotech, Am Klopferspitz 19, 82152 Martinsried, Germany.
4
Department of Molecular and Medical Virology, Ruhr-University Bochum, Universitätsstraße 150, 44790 Bochum, Germany; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Schloßgarten 4, 91054 Erlangen, Germany. Electronic address: matthias.tenbusch@fau.de.

Abstract

Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we compared the immunogenicity and efficacy of E1/E3-deleted Ad19a vectors encoding the influenza A virus (IAV)-derived antigens hemagglutinin (HA) and nucleoprotein (NP) to the most commonly used Ad5 vectors. The adenoviral vectors were applied intranasally and induced detectable antigen-specific T cell responses in the lung and in the spleen as well as robust antibody responses. A prior DNA immunization significantly improved the immunogenicity of both vectors and resulted in full protection against a lethal infection with a heterologous H3N2 virus. Nevertheless, the Ad5-based vectors were slightly superior in reducing viral replication in the lung which corresponded to higher NP-specific T cell responses measured in the lungs.

KEYWORDS:

Ad19a; Ad5; Adenoviral vectors; Influenza A virus; Mucosal vaccines

PMID:
29628150
DOI:
10.1016/j.vaccine.2018.02.075
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center